Bone-Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer: Evolving Paradigms
Majority of patients with metastatic castrate resistant prostate cancer (mCRPC) develop bone metastases which results in significant morbidity and mortality as a result of skeletal-related events (SREs). Several bone-targeted agents are either in clinical use or in development for prevention of SREs...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | Prostate Cancer |
| Online Access: | http://dx.doi.org/10.1155/2013/210686 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832548531268747264 |
|---|---|
| author | Joelle El-Amm Ashley Freeman Nihar Patel Jeanny B. Aragon-Ching |
| author_facet | Joelle El-Amm Ashley Freeman Nihar Patel Jeanny B. Aragon-Ching |
| author_sort | Joelle El-Amm |
| collection | DOAJ |
| description | Majority of patients with metastatic castrate resistant prostate cancer (mCRPC) develop bone metastases which results in significant morbidity and mortality as a result of skeletal-related events (SREs). Several bone-targeted agents are either in clinical use or in development for prevention of SREs. Bisphosphonates were the first class of drugs investigated for prevention of SREs and zoledronic acid is the only bisphosphonate that is FDA-approved for this indication. Another bone-targeted agent is denosumab which is a fully humanized monoclonal antibody that binds to the RANK-L thereby inhibiting RANK-L mediated bone resorption. While several radiopharmaceuticals were approved for pain palliation in mCRPC including strontium and samarium, alpharadin is the first radiopharmaceutical to show significant overall survival benefit. Contemporary therapeutic options including enzalutamide and abiraterone have effects on pain palliation and SREs as well. Other novel bone-targeted agents are currently in development, including the receptor tyrosine kinase inhibitors cabozantinib and dasatinib. Emerging therapeutics in mCRPC has resulted in great strides in preventing one of the most significant sources of complications of bone metastases. |
| format | Article |
| id | doaj-art-3611ab45bbf141ee99d96aa5ba570ab7 |
| institution | Kabale University |
| issn | 2090-3111 2090-312X |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Prostate Cancer |
| spelling | doaj-art-3611ab45bbf141ee99d96aa5ba570ab72025-02-03T06:13:47ZengWileyProstate Cancer2090-31112090-312X2013-01-01201310.1155/2013/210686210686Bone-Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer: Evolving ParadigmsJoelle El-Amm0Ashley Freeman1Nihar Patel2Jeanny B. Aragon-Ching3Division of Hematology/Oncology, Department of Medicine, George Washington University Medical Center, 2150 Pennsylvania Avenue NW, Washington, DC 20037, USADepartment of Medicine, George Washington University Medical Center, Washington, DC 20037, USADivision of Hematology/Oncology, Department of Medicine, George Washington University Medical Center, 2150 Pennsylvania Avenue NW, Washington, DC 20037, USADivision of Hematology/Oncology, Department of Medicine, George Washington University Medical Center, 2150 Pennsylvania Avenue NW, Washington, DC 20037, USAMajority of patients with metastatic castrate resistant prostate cancer (mCRPC) develop bone metastases which results in significant morbidity and mortality as a result of skeletal-related events (SREs). Several bone-targeted agents are either in clinical use or in development for prevention of SREs. Bisphosphonates were the first class of drugs investigated for prevention of SREs and zoledronic acid is the only bisphosphonate that is FDA-approved for this indication. Another bone-targeted agent is denosumab which is a fully humanized monoclonal antibody that binds to the RANK-L thereby inhibiting RANK-L mediated bone resorption. While several radiopharmaceuticals were approved for pain palliation in mCRPC including strontium and samarium, alpharadin is the first radiopharmaceutical to show significant overall survival benefit. Contemporary therapeutic options including enzalutamide and abiraterone have effects on pain palliation and SREs as well. Other novel bone-targeted agents are currently in development, including the receptor tyrosine kinase inhibitors cabozantinib and dasatinib. Emerging therapeutics in mCRPC has resulted in great strides in preventing one of the most significant sources of complications of bone metastases.http://dx.doi.org/10.1155/2013/210686 |
| spellingShingle | Joelle El-Amm Ashley Freeman Nihar Patel Jeanny B. Aragon-Ching Bone-Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer: Evolving Paradigms Prostate Cancer |
| title | Bone-Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer: Evolving Paradigms |
| title_full | Bone-Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer: Evolving Paradigms |
| title_fullStr | Bone-Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer: Evolving Paradigms |
| title_full_unstemmed | Bone-Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer: Evolving Paradigms |
| title_short | Bone-Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer: Evolving Paradigms |
| title_sort | bone targeted therapies in metastatic castration resistant prostate cancer evolving paradigms |
| url | http://dx.doi.org/10.1155/2013/210686 |
| work_keys_str_mv | AT joelleelamm bonetargetedtherapiesinmetastaticcastrationresistantprostatecancerevolvingparadigms AT ashleyfreeman bonetargetedtherapiesinmetastaticcastrationresistantprostatecancerevolvingparadigms AT niharpatel bonetargetedtherapiesinmetastaticcastrationresistantprostatecancerevolvingparadigms AT jeannybaragonching bonetargetedtherapiesinmetastaticcastrationresistantprostatecancerevolvingparadigms |